ContraVir Pharmaceuticals to Present CRV431 Phase 1 Data at the International Liver Congress™
11 Abril 2019 - 9:00AM
ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical
company focused on the development of therapeutic drugs for the
treatment of liver disease arising from non-alcoholic
steatohepatitis (NASH) and chronic viral infection, today announced
that it will present a poster on a Phase 1 single ascending dose
study of CRV431 at the 53rd Annual International Liver
Congress™ 2019 (EASL), taking place in Vienna, Austria from April
10-14, 2019.
Dr. Daren Ure, Director of Research and
Development, ContraVir Pharmaceuticals, Inc. will present a
study where subjects were treated with escalating doses of CRV431
administered as a single dose to assess safety, tolerability and
pharmacokinetic profiles.
Robert Foster, PharmD, PhD, Chief Executive
Officer of ContraVir Pharmaceuticals, said, “We are pleased to be
invited to present this poster at EASL 2019 as it forms the basis
of our continued development of CRV431, a promising therapeutic
candidate for hepatitis B and liver disease.”
Presentation Details
A Phase 1 Single Ascending Dose Study of
CRV431Poster presentation number:
FRI-171Authors: Danielle Armas1, Michael Snyder2, Daniel
Trepanier2, Daren Ure2, Jill Greytok2, Robert Foster2 1Celerion,
Tempe, AZ, USA; 2Contravir Pharmaceuticals, Inc., Edison, NJ, USA
and Edmonton, AB, Canada Date: Friday April 12, 2019
About CRV431
CRV431 is a clinical stage cycliphilin
inhibitor. Its primary biochemical action is inhibition of
cyclophilin isomerase activity, which is known to play a key role
in protein folding. In non-clinical, experimental models of NASH,
CRV431 reduced fibrosis scores and hepatocellular carcinoma (HCC)
tumor burden. In addition, CRV431 has also shown activity against
certain viruses including HBV, HCV, and HIV-1. CRV431 has
demonstrated an ability to reduce multiple markers of HBV infection
including reductions in DNA, HBsAg, HBeAg, and HBV uptake by liver
cells. These multiple modes of action may play an important role in
the overall treatment of liver disease, from triggering events
through to end-stage liver disease. CRV431 has completed phase 1
human clinical trials.
About ContraVir
Pharmaceuticals
ContraVir is a biopharmaceutical company focused
on the development of targeted therapies for liver disease arising
from non-alcoholic steatohepatitis (NASH) and chronic hepatitis B,
C and D viruses (HBV, HVC, HDV). The company’s lead drug candidate
is CRV431, a novel cyclophilin inhibitor. In
vitro and in vivo studies have thus far demonstrated
that CRV431 reduces liver fibrosis and hepatocellular carcinoma
tumor burden. CRV431 is also a host-targeting antiviral that
reduces important viral proteins, such as those involved in host
cell entry and viral replication. For more information, please
visit www.contravir.com.
Forward Looking
Statements
Certain statements in this press release are
forward-looking within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements may be
identified by the use of forward-looking words such as
“anticipate,” “believe,” “forecast,” “estimated,” and “intend,”
among others. These forward-looking statements are based on
ContraVir’s current expectations and actual results could differ
materially. There are a number of factors that could cause
actual events to differ materially from those indicated by such
forward-looking statements. These factors include, but are not
limited to, substantial competition; our ability to continue as a
going concern; our need for additional financing; uncertainties of
patent protection and litigation; uncertainties with respect to
lengthy and expensive clinical trials, that results of earlier
studies and trials may not be predictive of future trial results;
uncertainties of government or third party payer reimbursement;
limited sales and marketing efforts and dependence upon third
parties; and risks related to failure to obtain FDA clearances or
approvals and noncompliance with FDA regulations. As with any drug
candidates under development, there are significant risks in the
development, regulatory approval, and commercialization of new
products. There are no guarantees that future clinical trials
discussed in this press release will be completed or successful, or
that any product will receive regulatory approval for any
indication or prove to be commercially successful. ContraVir
does not undertake an obligation to update or revise any
forward-looking statement. Investors should read the risk factors
set forth in ContraVir’s Form 10-K for the year ended December
30, 2017 and other periodic reports filed with the Securities and
Exchange Commission.
For further information, please contact:
Stephen KilmerContraVir Investor Relations(646)
274-3580skilmer@contravir.com
Contravir Pharmaceuticals Inc (NASDAQ:CTRV)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Contravir Pharmaceuticals Inc (NASDAQ:CTRV)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024